-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] Renfu Pharmaceutical recently announced that its holding subsidiary, Yichang Renfu, has recently received the "Drug Registration Certificate" approved and issued by the State Food and Drug Administration on the increase of indications for remazolam besylate for injecti.
Its announcement stated that after the approval of the new indication of remazolam besylate for injection, it will help to expand the scope of use of the product and bring positive impact to the compa.
According to the announcement, Remazolam besylate for injection is a new benzodiazepine drug jointly developed by Yichang Renfu and German company PAI.
It is an ultra-short-acting GABAa receptor agonist with the characteristics of water solubility and short elimination half-li.
The new indications approved this time are: sedation for bronchoscopy diagnosis and treatme.
Up to now, Yichang Renfu has invested about RMB 120 million in the proje.
According to the announcement, Yichang Renfu first submitted a marketing application for remazolam besylate for injection to the State Food and Drug Administration in November 2018, and was approved for marketing in July 2020, with the approved indication being "for colonic us.
Sedation for microscop.
The new indication approved in March 2022 is "general anesthesia induction and maintenanc.
In 2021, the market sales of Remazolam Besylate for Yichang Renfu Injection will be approximately RMB 60 milli.
In January 2022, Wuhan Renfu Innovative Drug Research and Development Center .
, L.
, a wholly-owned subsidiary of the company, acquired the ownership of remazolam besylate in mainland China and Hong Kong held by PAI.
The main business of Renfu Pharmaceutical is the research and development, production, sales and technical services of medicines, medical devices, reproductive health and other products and technologies; real estate development and sal.
In recent years, Renfu Medicine has continued to increase pharmaceutical innovation research and developme.
According to data, from 2019 to 2021, Renfu Medicine's R&D investment was 760 million yuan, 940 million yuan, and 05 billion yuan, accounting for more than 10% of the company's pharmaceutical industry reven.
The annual increase in investment is more than 1
The company said that it is expected to have national first-class new drugs approved and listed in the three major fields of chemical medicine, traditional Chinese medicine and biological medicine, and realize the R&D and innovation pattern of the rational distribution of innovative drugs, first generic drugs and other generic dru.
It is reported that in addition to the approval of the new indications of remazolam besylate for injection recently, Renfu Medicine, the company's holding subsidiary, Yichang Renfu, has also received the "Drug Clinical Application" for RFUS-144 injection approved and issued by the State Drug Administrati.
Test Approval Noti.
RFUS-144 injection is intended to be clinically used for the treatment of pain and prurit.
It is a selective opioid receptor agonist, and there is currently no similar product on the market in Chi.
In June, the company's subsidiary Wuhan Puke also received the approval of the State Drug Administration to issue the "Drug Registration Certificate" for the release of profen soft capsul.
This time, the ibuprofen soft capsules obtained the "Drug Registration Certificate" in Chi.
Consistency evaluation of pharmaceutical quality and effica.
Data show that ibuprofen is used to relieve mild to moderate pain such as arthralgia, neuralgia, muscle pain, migraine, headache, dysmenorrhea, toothache, and can also be used for fever caused by the common cold or influen.
According to the industry, after the implementation of "return to core and focus", Renfu Medicine has been quite effective in terms of the development of core busine.
After the approval of remazolam besylate for injection of Class 1 new chemical drug in 2020, it was approved in May 2021 for fospropofol disodium for injection of Class 1 new chemical dr.
According to relevant data, in 2021, the Pharmaceutical Research Institute of Renfu Pharmaceutical Group will establish 41 new projects and 9 innovative drug projects in the clinical sta.
In terms of the consistency evaluation of generic drugs, as of the end of 2021, Renfu Medicine has 37 varieties of a total of 58 products that have passed the consistency evaluation of generic drugs (including deemed passed), of which 7 products are the first to pass the evaluati.
In addition, the company's new class 1 traditional Chinese medicine drug Guangjincao total flavonoid capsules have been declared for production, and the recombinant plasmid-hepatocyte growth factor injection, a class 1 new biological drug drug, is in Phase III clinical tria.
Data shows that in recent years, Renfu Medicine has also achieved good results in performan.
For example, in 2021, its operating income after excluding the consolidation factor is 2441 billion yuan, and the net profit attributable to shareholders of listed companies will increase by about 21% year-on-year to 390 billion yuan; the non-net profit attributable to shareholders of listed companies will increase by about 41% year-on-year to 178 billi.
In addition, according to the company's recently released performance forecast data for the first half of 2022, the company expects that the net profit attributable to shareholders of listed companies in the first half of 2022 will be 55 billion to 65 billion yuan, a year-on-year increase of 134% to 14
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Its announcement stated that after the approval of the new indication of remazolam besylate for injection, it will help to expand the scope of use of the product and bring positive impact to the compa.
According to the announcement, Remazolam besylate for injection is a new benzodiazepine drug jointly developed by Yichang Renfu and German company PAI.
It is an ultra-short-acting GABAa receptor agonist with the characteristics of water solubility and short elimination half-li.
The new indications approved this time are: sedation for bronchoscopy diagnosis and treatme.
Up to now, Yichang Renfu has invested about RMB 120 million in the proje.
According to the announcement, Yichang Renfu first submitted a marketing application for remazolam besylate for injection to the State Food and Drug Administration in November 2018, and was approved for marketing in July 2020, with the approved indication being "for colonic us.
Sedation for microscop.
The new indication approved in March 2022 is "general anesthesia induction and maintenanc.
In 2021, the market sales of Remazolam Besylate for Yichang Renfu Injection will be approximately RMB 60 milli.
In January 2022, Wuhan Renfu Innovative Drug Research and Development Center .
, L.
, a wholly-owned subsidiary of the company, acquired the ownership of remazolam besylate in mainland China and Hong Kong held by PAI.
The main business of Renfu Pharmaceutical is the research and development, production, sales and technical services of medicines, medical devices, reproductive health and other products and technologies; real estate development and sal.
In recent years, Renfu Medicine has continued to increase pharmaceutical innovation research and developme.
According to data, from 2019 to 2021, Renfu Medicine's R&D investment was 760 million yuan, 940 million yuan, and 05 billion yuan, accounting for more than 10% of the company's pharmaceutical industry reven.
The annual increase in investment is more than 1
The company said that it is expected to have national first-class new drugs approved and listed in the three major fields of chemical medicine, traditional Chinese medicine and biological medicine, and realize the R&D and innovation pattern of the rational distribution of innovative drugs, first generic drugs and other generic dru.
It is reported that in addition to the approval of the new indications of remazolam besylate for injection recently, Renfu Medicine, the company's holding subsidiary, Yichang Renfu, has also received the "Drug Clinical Application" for RFUS-144 injection approved and issued by the State Drug Administrati.
Test Approval Noti.
RFUS-144 injection is intended to be clinically used for the treatment of pain and prurit.
It is a selective opioid receptor agonist, and there is currently no similar product on the market in Chi.
In June, the company's subsidiary Wuhan Puke also received the approval of the State Drug Administration to issue the "Drug Registration Certificate" for the release of profen soft capsul.
This time, the ibuprofen soft capsules obtained the "Drug Registration Certificate" in Chi.
Consistency evaluation of pharmaceutical quality and effica.
Data show that ibuprofen is used to relieve mild to moderate pain such as arthralgia, neuralgia, muscle pain, migraine, headache, dysmenorrhea, toothache, and can also be used for fever caused by the common cold or influen.
According to the industry, after the implementation of "return to core and focus", Renfu Medicine has been quite effective in terms of the development of core busine.
After the approval of remazolam besylate for injection of Class 1 new chemical drug in 2020, it was approved in May 2021 for fospropofol disodium for injection of Class 1 new chemical dr.
According to relevant data, in 2021, the Pharmaceutical Research Institute of Renfu Pharmaceutical Group will establish 41 new projects and 9 innovative drug projects in the clinical sta.
In terms of the consistency evaluation of generic drugs, as of the end of 2021, Renfu Medicine has 37 varieties of a total of 58 products that have passed the consistency evaluation of generic drugs (including deemed passed), of which 7 products are the first to pass the evaluati.
In addition, the company's new class 1 traditional Chinese medicine drug Guangjincao total flavonoid capsules have been declared for production, and the recombinant plasmid-hepatocyte growth factor injection, a class 1 new biological drug drug, is in Phase III clinical tria.
Data shows that in recent years, Renfu Medicine has also achieved good results in performan.
For example, in 2021, its operating income after excluding the consolidation factor is 2441 billion yuan, and the net profit attributable to shareholders of listed companies will increase by about 21% year-on-year to 390 billion yuan; the non-net profit attributable to shareholders of listed companies will increase by about 41% year-on-year to 178 billi.
In addition, according to the company's recently released performance forecast data for the first half of 2022, the company expects that the net profit attributable to shareholders of listed companies in the first half of 2022 will be 55 billion to 65 billion yuan, a year-on-year increase of 134% to 14
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
